Research programme: small molecule therapeutics - Sharp Edge Labs

Drug Profile

Research programme: small molecule therapeutics - Sharp Edge Labs

Alternative Names: chemical chaperone therapeutics

Latest Information Update: 26 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sharp Edge Labs
  • Class Small molecules
  • Mechanism of Action Protein folding modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease; Cystic fibrosis; Dementia; Lysosomal-storage diseases; Parkinson's disease

Most Recent Events

  • 24 Mar 2016 Sharp Edge Labs and ORIG3N agree to co-develop small molecule therapeutics in USA for Alzheimer's disease, Cystic fibrosis, Dementia, Lysosomal storage diseases and Parkinson's disease
  • 24 Mar 2016 Sharp Edge Labs in-licenses Fluorogen Activating Module technology technology from Carnegie Mellon University before March 2016 (Sharp Edge Labs' website, March 2016)
  • 24 Mar 2016 Early research in Alzheimer's disease, Cystic fibrosis, Dementia, Lysosomal storage diseases, Parkinson's disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top